4 Biotech Stocks Most Wall Street Analysts Are Bullish About

Zacks12-20 02:24

It was a choppy ride for the biotech sector in 2024. While the year started on a positive note, much of the gains were pared thereafter, and the sector is down 10.5% as of now. New drug approvals and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492248565?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VCILzt0LKKaSV5FPHCcbXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e","is_english":true,"pubTime":"2024-12-20 02:24","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492248565","market":"us","top_or_hot":-1,"title":"4 Biotech Stocks Most Wall Street Analysts Are Bullish About","media":"Zacks","content":"<div>\n<p>It was a choppy ride for the biotech sector in 2024. While the year started on a positive note, much of the gains were pared thereafter, and the sector is down 10.5% as of now. New drug approvals and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/4-biotech-stocks-most-wall-182400070.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Biotech Stocks Most Wall Street Analysts Are Bullish About</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Biotech Stocks Most Wall Street Analysts Are Bullish About\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 02:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/4-biotech-stocks-most-wall-182400070.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It was a choppy ride for the biotech sector in 2024. While the year started on a positive note, much of the gains were pared thereafter, and the sector is down 10.5% as of now. New drug approvals and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/4-biotech-stocks-most-wall-182400070.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0009355771.USD","symbol_name":"骏利亨德森环球生命科技A Acc","start_time":0,"source_url":"https://finance.yahoo.com/news/4-biotech-stocks-most-wall-182400070.html","article_id":"2492248565","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VCILzt0LKKaSV5FPHCcbXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/829e973ee4e0f9b8c53ec82f52e62f8e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492248565","pubTimestamp":1734632640,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"It was a choppy ride for the biotech sector in 2024. While the year started on a positive note, much of the gains were pared thereafter, and the sector is down 10.5% as of now. New drug approvals and a surge in mergers and acquisitions (M&A) activity were expected to keep the sector going in 2024, but a slowdown in collaboration deals despite a drop in interest rates and market volatility hit hard.Nonetheless, given the continuous need for innovative medical treatments, irrespective of the state of the economy, the biotech industry will continue to grab investors’ interest despite the inherent volatility and uncertain macroeconomic environment.M&A activity will likely accelerate in 2025 with a change in administration and expected deregulation. Pharma and biotech bigwigs always look to bolster their product portfolios and pipelines through collaborations and buyouts. While oncology and immunooncology companies have always been acquisition targets, those with obesity drugs in their port","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SRPT":"Sarepta Therapeutics","BK4548":"巴美列捷福持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","ALNY":"阿尔尼拉姆制药公司","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4588":"碎股","EXEL":"伊克力西斯","ADMA":"ADMA Biologics Inc","BK4532":"文艺复兴科技持仓"},"translate_title":"大多数华尔街分析师看好的4只生物科技股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1,"ALNY":1,"SRPT":1,"EXEL":0.9},"content_text":"It was a choppy ride for the biotech sector in 2024. While the year started on a positive note, much of the gains were pared thereafter, and the sector is down 10.5% as of now. New drug approvals and a surge in mergers and acquisitions (M&A) activity were expected to keep the sector going in 2024, but a slowdown in collaboration deals despite a drop in interest rates and market volatility hit hard.\nNonetheless, given the continuous need for innovative medical treatments, irrespective of the state of the economy, the biotech industry will continue to grab investors’ interest despite the inherent volatility and uncertain macroeconomic environment.\nM&A activity will likely accelerate in 2025 with a change in administration and expected deregulation. Pharma and biotech bigwigs always look to bolster their product portfolios and pipelines through collaborations and buyouts.  While oncology and immunooncology companies have always been acquisition targets, those with obesity drugs in their portfolio/pipeline and gene-editing companies hold great potential. This, in turn, will put the spotlight on smaller biotech companies with promising candidates in their kitty.\nHere, we discuss four biotech stocks that put up a robust show in 2024 and are likely to maintain the same in 2025 on the back of a solid portfolio and a promising pipeline. These are Sarepta Therapeutics SRPT, ADMA Biologics ADMA, Exelixis EXEL and Alnylam Pharmaceuticals ALNY.\nImage Source: Zacks Investment Research\nSarepta Therapeutics\nSarepta’s portfolio received a significant boost with the FDA approval for Elevidys — the first-ever gene therapy for the Duchenne muscular dystrophy (DMD) indication.  Since its launch, the gene therapy has demonstrated blockbuster potential. In June 2024, the FDA granted label expansion approval to Elevidys to treat all DMD patients aged four years and older.\nSRPT is also working to add new gene therapy treatments to its portfolio. It is developing gene therapy programs for Limb-girdle muscular dystrophy (LGMD) and plans to submit a regulatory filing with the FDA in mid-2025 for its LGMD candidate, SRP-9003. The company is also developing potential therapeutic candidates for other neuromuscular and central nervous system disorders.\nApart from Elevidys, Sarepta has three other therapies — Exondys 51, Vyondys 53 and Amondys 45 — in its commercial portfolio targeting the DMD patient population.\nSarepta has put up a strong performance in 2024, with shares surging 24.7%. Positive regulatory updates and good pipeline progress should help the stock gain further. The current average target price of $184.15 for SRPT represents an upside of 46.43%.\nSRPT currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nADMA Biologics\nADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and prevention of certain infectious diseases.\nThe targeted market has significant potential. Asceniv is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies. Its strong sales growth is driving the top line. The ongoing post-marketing study for Asceniv may provide a label expansion opportunity to include pediatric-aged PI patients. Incremental additional penetration of Asceniv should accelerate near-term revenue growth.\nADMA’s higher-margin product portfolio now accounts for more than 50% of its total revenues. The company is working to increase Asceniv's supply. If successful, Asceniv will account for a significant portion of ADMA's total revenues over time, further advancing its potential margin expansion and earnings growth.\nThe company has put up a stupendous performance in 2024, buoyed by strong quarterly performances and a consecutive increase in guidance. Shares have skyrocketed 291.6% so far in 2024.\nThe stock currently carries a Zacks Rank #2. Earnings per share (EPS) estimates for 2024 and 2025 have increased 3 and 14 cents, respectively, in the past 60 days. The current average target price of $25 for ADMA represents an upside of 34.19%.\nExelixis\nExelixis has been a consistent outperformer of late on the back of the strong performance of its lead drug, Cabometyx, and encouraging pipeline progress. Cabometyx maintains its status as the leading tyrosine kinase inhibitor (TKI) for the treatment of renal cell carcinoma. This is mainly attributable to its use in combination with Opdivo in the first-line setting. The drug also maintained growth in the hepatocellular carcinoma indication.\nManagement is focused on the label expansion of Cabometyx. The FDA accepted EXEL’s supplemental new drug application (sNDA) for cabozantinib for patients with previously treated advanced pancreatic neuroendocrine tumors (pNET) and those with previously treated advanced extra-pancreatic NET (epNET). It also assigned a standard review with a target action date of April 3, 2025, and granted the orphan drug designation to cabozantinib for the treatment of pNET. A potential label expansion should further propel its growth prospects.\nThe pipeline progress has also been impressive as Exelixis looks to expand its oncology portfolio beyond Cabometyx; another promising candidate in Exelixis’ pipeline is zanzalintinib, a next-generation oral TKI.\nThe company is also making efforts to increase shareholder value through repurchases.\nEXEL currently carries a Zacks Rank 2. Shares of the company have surged 40.3% so far in 2024. EPS estimates for 2024 and 2025 have gained 10 cents and 14 cents, respectively.\nAlnylam Pharmaceuticals\nAlnylam’s marketed drugs, Amvuttra, Givlaari and Oxlumo, are performing well. The strong uptake of Amvuttra is being driven by new patients starting treatment as well as patient switches from Onpattro. The company is also working to expand Amvuttra’s label, which should further fuel sales.\nAlnylam has collaborated with Regeneron, Sanofi and Roche among others to advance its pipeline. It also has a deep pipeline with promising candidates, namely cemdisiran, mivelsiran and zilebesiran. The successful development and commercialization of all these candidates would be a huge boost for the company.\nALNY currently carries a Zacks Rank 2. Shares of the company have surged 24.3% year to date. Loss per share estimates for 2024 and 2025 have narrowed 4 cents and 35 cents, respectively. The current average target price of $296.32 for ALNY represents an upside of 24.55%. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAlnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report\nExelixis, Inc. (EXEL) : Free Stock Analysis Report\nSarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report\nADMA Biologics Inc (ADMA) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492248565"}